Sugi Predict

Sugi Predict / Compounds / SCHEMBL400626

SCHEMBL400626

SCHEMBL400626

Nc1ncnc2c1c(I)cn2C1CCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 10/20 0.61
▸ ABL1 P00519 9/20 0.61
▸ EGFR P00533 8/20 0.61
▸ ABL2 P42684 8/20 0.61
▸ RET P07949 4/20 0.60
▸ LCK P06239 2/20 0.60
▸ CSF1R P07333 2/20 0.60
▸ IGF1R P08069 2/20 0.60
▸ FGFR1 P11362 2/20 0.60
▸ FLT1 P17948 2/20 0.60
▸ KDR P35968 2/20 0.60
▸ FLT3 P36888 2/20 0.60
▸ MST1R Q04912 2/20 0.60
▸ NTRK3 Q16288 2/20 0.60
▸ NTRK2 Q16620 2/20 0.60
▸ ALK Q9UM73 2/20 0.60
▸ DAPK3 O43293 1/20 0.60
▸ MAP4K4 O95819 1/20 0.60
▸ PAK4 O96013 1/20 0.60
▸ FYN P06241 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29484468 1.00 SRC (0.61) SRCABL1EGFRABL2RET
SCHEMBL1940882 0.97 ABL1 (0.64) SRCABL1EGFRABL2RET
SCHEMBL30155310 0.97 ABL1 (0.64) SRCABL1EGFRABL2RET
SCHEMBL17818397 0.95 ABL1 (0.63) SRCABL1EGFRABL2RET
SCHEMBL16237288 0.94 SRC (0.59) SRCABL1EGFRABL2RET
SCHEMBL1933267 0.88 RIPK2 (0.63) SRCABL1RETLCKCSF1R
SCHEMBL1933264 0.88 RIPK2 (0.63) SRCABL1RETLCKCSF1R
SCHEMBL9950847 0.87 ADK (0.62) SRCABL1EGFRABL2RET
SCHEMBL9950846 0.87 ADK (0.62) SRCABL1EGFRABL2RET
SCHEMBL19743649 0.87 FGR (0.57) SRCABL1EGFRABL2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317758-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-09-26 — — US disclosed
US-12091413-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2024-09-17 — — US disclosed
EP-4146348-B1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2024-07-03 — — EP disclosed
US-20240158394-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-05-16 — — US disclosed
WO-2024059200-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-03-21 — — WO disclosed
CN-117597346-A NEK7 inhibitors 哈利亚治疗公司 2024-02-23 — — CN disclosed
EP-4320127-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-02-14 — — EP disclosed
US-20230416259-A1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2023-12-28 — — US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 — — US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 — — US disclosed
EP-2168968-A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, Inc. (US) 2010-03-31 — — EP disclosed
EP-2168968-A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, Inc. (US) 2010-03-31 — — EP disclosed
US-20090325928-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-12-31 — — US disclosed
US-20090325928-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-12-31 — — US disclosed
US-7534797-B2 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-05-19 — — US disclosed
US-7534797-B2 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-05-19 — — US disclosed
US-7534797-B2 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-05-19 — — US disclosed
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-05-07 — — US disclosed
CN-1960993-A 6, 6-bicyclic substituted heterobicyclic protein kinase inhibitors OSI PHARM INC (US) 2007-05-09 — — CN disclosed
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325928-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 SRC 299/4885ABL1 621/4885EGFR 155/4885
US-11713321-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 SRC 639/4885ABL1 2321/4885EGFR 4553/4885
US-12091413-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 SRC 639/4885ABL1 2321/4885EGFR 4553/4885
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 SRC 299/4885ABL1 621/4885EGFR 155/4885
US-20240317758-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 SRC 1649/4885ABL1 4219/4885EGFR 4852/4885
US-20240158394-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 SRC 1597/4885ABL1 3937/4885EGFR 4857/4885
US-20230416259-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 SRC 639/4885ABL1 2321/4885EGFR 4553/4885
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors IGF1R, MAP2K7, BRCA1 SRC 299/4885ABL1 621/4885EGFR 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.